AbbVie Inc. (ABBV)
- Sector
- Health Care
- Industry
- Biotechnology
- Last price
- $274.36
- As of
Kresmion compiles this page from ABBV's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
AbbVie Inc. (ABBV): 6 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-10-05.
See the full ABBV dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for ABBV on one page. Preview it with sample data, then open it live with a free account.
Preview the ABBV dossierActive signals for ABBV
- highFDA_APPROVAL
FDA approves drug (AbbVie)
- highCONSENSUS_BUY
4 tracked funds increased ABBV this 2026Q2, institutional consensus
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +121% to ABBV (2026Q2)
- highINSTITUTIONAL_EXIT
Point72 Asset Management, L.P. cut 56% of ABBV (2026Q2)
- highINSTITUTIONAL_SURGE
Point72 Asset Management, L.P. added +1530% to ABBV (2026Q2)
FREE, NO ACCOUNT
Every signal on ABBV, as it fires
You are seeing 5 of 126 signals recorded on ABBV since 2026-04-29.
The five above landed across 3 days. The other 121 were recorded on 31 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in ABBV (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| CITADEL ADVISORS LLCCUSIP 00287Y109 · 2026Q2 | $797.6M | 0.09% | , |
| D. E. Shaw & Co., Inc.CUSIP 00287Y109 · 2026Q2 | $529M | 0.25% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 00287Y109 · 2026Q2 | $381.6M | 0.14% | , |
| Point72 Asset Management, L.P.CUSIP 00287Y109 · 2026Q2 | $92.3M | 0.10% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 00287Y109 · 2026Q2 | $49.9M | 0.04% | , |
| Bridgewater Associates, LPCUSIP 00287Y109 · 2026Q2 | $3M | 0.01% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, ABBV
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
ABBV against its peers
ABBV's operating margin of 24.6% ranks in the 50th percentile of 20 Biotechnology sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-03-31.
| Metric | ABBV | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 61.2B USD | 3.0B USD | 98 | 20 |
| Operating margin | 24.6% | 23.2% | 50 | 20 |
| Net margin | 6.9% | 16.7% | 39 | 21 |
| Return on equity | n/a | 14.4% | n/a | 21 |
| P / E | 116.3x | 26.5x | 96 | 11 |
| 1 year | 19.1% | 29.8% | 33 | 19 |
Peers (23): AMGN, GILD, VRTX, MRNA, REGN, NTRA, ARGX, RVMD, ONC, BIIB, ALNY, ROIV, RPRX, BNTX, UTHR, INCY, GMAB, INSM, ASND, EXEL, NBIX, SMMT, BBIO. Left out: CSLLY (no annual filing), IVBXF (no annual filing). Fiscal periods ending between 2025-12-31 and 2026-03-31. Every figure is one full fiscal year read from one annual filing (ABBV: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow ABBV on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to ABBV for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.